ArriVent BioPharma (NASDAQ:AVBP) Releases Quarterly Earnings Results, Beats Expectations By $0.23 EPS

ArriVent BioPharma (NASDAQ:AVBP) announced its quarterly earnings data on Monday. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.23, FiscalAI reports. The company had revenue of $5.00 million during the quarter, compared to analyst estimates of $0.80 million.

ArriVent BioPharma Price Performance

Shares of AVBP traded up $0.52 on Monday, reaching $14.16. 905,956 shares of the stock traded hands, compared to its average volume of 746,557. The firm has a market cap of $698.20 million, a price-to-earnings ratio of -3.91 and a beta of 1.66. ArriVent BioPharma has a 12 month low of $11.36 and a 12 month high of $35.83. The stock’s 50-day moving average price is $23.05 and its 200-day moving average price is $26.66.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on AVBP shares. BTIG Research reiterated a “buy” rating and set a $29.00 target price on shares of ArriVent BioPharma in a research note on Friday, October 16th. Guggenheim raised their price target on shares of ArriVent BioPharma from $18.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, October 27th. Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a report on Tuesday, September 22nd. JonesTrading cut their price objective on shares of ArriVent BioPharma from $45.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th. Finally, Wall Street Zen upgraded shares of ArriVent BioPharma from a “strong sell” rating to a “sell” rating in a research note on Sunday, October 18th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $24.56.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision oncology therapies for patients with genetically defined cancers. The company’s primary focus is on targeted treatments for non-small cell lung cancer (NSCLC), particularly tumors driven by mutations in the epidermal growth factor receptor (EGFR) gene.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible EGFR tyrosine kinase inhibitor designed to target a range of EGFR mutations, including common mutations and exon 20 insertion mutations.